The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 31, 2021
Filed:
May. 04, 2018
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Jingtai Cao, White Plains, NY (US);
Eunice Cheung, Tarrytown, NY (US);
Ivan B. Lobov, New York, NY (US);
Assignee:
Regeneren Pharmaceuticals, Inc., Tarrytown, NY (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61P 27/02 (2006.01); A61K 38/17 (2006.01); C07K 14/72 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C07K 14/705 (2006.01); C07K 14/47 (2006.01); C07K 14/575 (2006.01); C07K 14/475 (2006.01); C07K 14/71 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 38/17 (2013.01); A61K 39/3955 (2013.01); A61P 27/02 (2018.01); C07K 14/47 (2013.01); C07K 14/705 (2013.01); C07K 14/72 (2013.01); C07K 16/2869 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 14/475 (2013.01); C07K 14/575 (2013.01); C07K 14/71 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract
The present disclosure provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutic composition comprising an APLNR antagonist such as an anti-APLNR antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (for example, aflibercept).